54754-86-8Relevant academic research and scientific papers
Theoretical, Solid-State, and Solution Quantification of the Hydrogen Bond-Enhanced Halogen Bond
Decato, Daniel A.,Riel, Asia Marie S.,May, James H.,Bryantsev, Vyacheslav S.,Berryman, Orion B.
supporting information, p. 3685 - 3692 (2020/12/22)
Proximal noncovalent forces are commonplace in natural systems and understanding the consequences of their juxtaposition is critical. This paper experimentally quantifies for the first time a Hydrogen Bond-Enhanced Halogen Bond (HBeXB) without the complexities of protein structure or preorganization. An HBeXB is a halogen bond that has been strengthened when the halogen donor simultaneously accepts a hydrogen bond. Our theoretical studies suggest that electron-rich halogen bond donors are strengthened most by an adjacent hydrogen bond. Furthermore, stronger hydrogen bond donors enhance the halogen bond the most. X-ray crystal structures of halide complexes (X?=Br?, I?) reveal that HBeXBs produce shorter halogen bonds than non-hydrogen bond analogues. 19F NMR titrations with chloride highlight that the HBeXB analogue exhibits stronger binding. Together, these results form the foundation for future studies concerning hydrogen bonds and halogen bonds in close proximity.
UROTENSIN II RECEPTOR ANTAGONISTS
-
Page/Page column 44-45, (2009/01/20)
Compounds of the formula (I) wherein R1, R2, R3, R4, R5, R6, W, and Y are as described herein, or a tautomer, prodrug, solvate, or salt thereof. These compounds are useful as inhibitors of Urotensin II and are thus useful for treating a variety of disease
PYRIDINYL COMPOUNDS WHICH ARE USEFUL AS ANGIOTENSIN II ANTAGONISTS
-
, (2008/06/13)
The invention concerns pharmaceutically useful compounds of the formula I, in which R 1, R 2, R 3, R 4, R 5, R. sup.6, R 7, Rz, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment. STR1
